Risk of Venous Thromboembolism in Pregnant Women with Essential Thrombocythemia: A Systematic Review and Meta-Analysis
In women with essential thrombocythemia, the absolute risk of a venous thromboembolism in the postpartum period is above a threshold where postpartum low-molecular-weight heparin prophylaxis should be considered. The absolute risk of venous thromboembolism in the antepartum period is not above a threshold where antepartum low-molecular-weight heparin is clearly indicated or below a threshold where low-molecular-weight heparin should be withheld. Thus, a preferences and values-based discussion is important when counseling women with essential thrombocythemia in pregnancy.
Blood
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology